DYRITON TABLET 4MG

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

CHLORPHENIRAMINE MALEATE

Boleh didapati daripada:

DYNAPHARM (M) SDN BHD

INN (Nama Antarabangsa):

CHLORPHENIRAMINE MALEATE

Unit dalam pakej:

1000 Tablets

Dikeluarkan oleh:

DYNAPHARM (M) SDN BHD

Risalah maklumat

DYRITON TABLET/SYRUP
Chlorpheniramine Maleate (4mg, 4mg/5ml)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What DYRITON_ _is used for
2.
How DYRITON_ _works
3.
Before you use DYRITON
4.
How to use DYRITON
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of DYRITON
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT DYRITON IS USED FOR
DYRITON is used for:
-
Palliative (relief) treatment of

hay-fever
and
vasomotor
(non-
allergic) rhinitis (inflammation of
the lining inside the nose)

Allergic
conjunctivitis
(redness
and inflammation of the thin layer
of tissue that covers the front of the
eye)

Mild, uncomplicated allergic skin
manifestations of urticaria (hives)
and
angioneurotic
oedema
(swelling that occurs just beneath
the surface of the skin or mucous
lining)

Drug
sensitisation
reactions
(reverse
of
tolerance
which
the
escalating
effect
of
a
medicine
resulting
from
repeated
doses
taken).
-
Amelioration (to make better or more
tolerable) of allergic reactions to blood
or
plasma,
foreign
proteins,
insect
bites and stings.
-
Relief
of
congestion
in
the
upper
respiratory
tract
associated
with
common cold or irritation arising from
dry, dusty climatic conditions.
HOW DYRITON WORKS
Chlorpheniramine
Maleate
is
an
antihistamine
which
reduces
allergic
symptoms.
The
antimuscarinic
action
provides
a
drying effect on the nose inner lining.
BEFORE YOU USE DYRITON
-
_When you must not use it _
It should not be given to premature
infants or newborn._ _
It is not recommended during acute
attacks of asthma._ _
_ _
_Pregnancy and lactation _
Tell your doctor if you are pregnant,
planning
to
become
pregnant
or
breastfeeding.
Use
during
the
third
trimester may result in reactions in
newborns. Chlorpheniramine maleate
may stop milk production and may be
found in breast milk. Ask your doctor
for advice before taking any medicine.
_ _
-
_Before you start to use it _
Tell your doctor if you have any of the
following conditions

Ciri produk

DYRITON
DESCRIPTION
CONTENT
DYRITON SYRUP 4MG/5ML
MAL19910170AZ
Dose Form :
SYRUP
Colour
:
Yellow
Flavour
:
Rose
Each 5 ml Contains:
Chlorpheniramine Maleate ..................... 4 mg
Preservatives: Methyl Paraben ............ 0.1% w/v
Propyl Paraben........... 0.01% w/v
Sodium Benzoate .......... 0.1% w/v
DYRITON TABLET 4MG
MAL19910162AZ
Dose Form :
TABLET
Colour
:
Yellow
Shape
:
Round, Flat and Scored
Each Tablet Contains:
Chlorpheniramine Maleate ..................... 4 mg
PHARMACODYNAMICS:
Chlorpheniramine Maleate is an antihistamine which acts by competing
with histamine for H1-receptor sites on effector cells. It
thereby prevents, but does not reverse, responses mediated by
histamine alone. The antimuscarinic action provides a drying
effect on the nasal mucosa.
PHARMACOKINETICS:
Chlorpheniramine Maleate is readily absorbed after oral
administration. After an oral dose, peak concentrations appear within
2
to 3 hours; the peak concentration after doses of up to 12 mg has been
variously reported as between 20 ng/ml and about 200
ng/ml. Plasma half-life after administration, has been reported as 12
to 15 hours.
It is widely distributed throughout the body tissues and appears to be
subject to enterohepatic circulation; protein binding,
about 70% bound to plasma proteins. It is extensively metabolised to
form polar and non-polar metabolites; 2 metabolites have
been identified as a result of N-demethylation and these are
mondesmethylchlorpheniramine and didesmethylchlorpheniramine.
About 35% of a dose is excreted in the urine in 48 hours; the
excretion of unchanged drug accounts for about 3 to 10% of the
dose but is increased by an increase in urinary pH and urinary flow.
Both demethylated metabolites are excreted in urine; less
than 1% of a dose is excreted in the faeces.
INDICATIONS:
For
palliative
treatment of hay-fever
and vasomotor
rhinitis; allergic
conjunctivitis; mild,
uncomplicated allergic
skin
manifestations of urticaria and angioneurotic oedema; drug
sensitisation reactions. For amelioration of allerg